Article

Whole genome mutational analysis for tumor-informed ctDNA based MRD surveillance, treatment monitoring and biological characterization of urothelial carcinoma

2023-07-13

Abstract excerpt

Circulating tumor DNA (ctDNA) can be used for sensitive detection of minimal residual disease (MRD). However, the probability of detecting ctDNA at low tumor burden is limited by the number of mutations analyzed and available plasma volume. Here we applied a tumor-informed whole genome sequencing (WGS) approach for ctDNA-based MRD detection (91% sensitivity, 92% specificity) and treatment response evaluation in 91...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0878ee38-1ebc-5eb9-94bf-23d9b040b3bf
DOI: 10.1101/2023.07.13.23292590

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Whole genome mutational analysis for tumor-informed ctDNA based MRD surveillance, treatment monitoring and biological characterization of urothelial carcinomaDOI 10.1101/2023.07.13.23292590Read

Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.Semantic proximity Read

High Sensitivity ctDNA Analysis Using a Novel Panel and NOIR-SS Technology for Monitoring Advanced Urothelial Carcinoma.Semantic proximity Read

Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer.Semantic proximity Read

Integrated Plasma and Urinary Cell-free DNA Profiling Enables Noninvasive Molecular Detection from Ta to T4 Bladder CancerSemantic proximity Read

The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration.Semantic proximity Read

Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling–informed personalized monitoring assaySemantic proximity Read

Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.Semantic proximity Read

Liquid Biopsy in Genitourinary Cancers: Circulating Tumor DNA as a Predictive Biomarker for Treatment Selection and Resistance MonitoringSemantic proximity Read

Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer.Semantic proximity Read

Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer.Semantic proximity Read

Circulating Tumor DNA in Genitourinary Malignancies: Current Applications and Future PerspectivesSemantic proximity Read

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.Semantic proximity Read